<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1995-4484-2020-290-293</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-2896</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Маркеры костного ремоделирования как предикторы метаболических изменений в костной ткани у мужчин с диабетической остеопатией</article-title><trans-title-group xml:lang="en"><trans-title>BONE REMODELING MARKERS AS PREDICTORS OF BONE METABOLIC CHANGES IN MALES WITH DIABETIC OSTEOPATHY</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7131-3878</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сафарова</surname><given-names>С. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Safarova</surname><given-names>S. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Саин Саттар Сафарова </p><p>AZ1022, Баку, ул. Бакиханова, 23 </p></bio><bio xml:lang="en"/><email xlink:type="simple">sainsafarova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6331-8233</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сафарова</surname><given-names>С. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Safarova</surname><given-names>S. S.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Азербайджанский медицинский университет</institution><country>Азербайджан</country></aff><aff xml:lang="en"><institution>Azerbaijan Medical University</institution><country>Azerbaijan</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>24</day><month>06</month><year>2020</year></pub-date><volume>58</volume><issue>3</issue><fpage>290</fpage><lpage>293</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Сафарова С.С., Сафарова С.С., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Сафарова С.С., Сафарова С.С.</copyright-holder><copyright-holder xml:lang="en">Safarova S.S., Safarova S.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/2896">https://rsp.mediar-press.net/rsp/article/view/2896</self-uri><abstract><p>Диабетическая остеопатия является одним из малоизученных осложнений сахарного диабета (СД), приводящим к частым низкотравматическим переломам и, как следствие, к инвалидизации и смертности. Уровень инсулина связан с функциональными и морфологическими изменениями костной ткани, предшествующими снижению минеральной плотности кости (МПК) на начальных стадиях диабетической остеопатии. Цель исследования – изучение морфофункциональных свойств кости у мужчин с СД 1-го (СД1) и 2-го типа (СД2). Материал и методы. Обследованы 41 пациент мужского пола с СД1 и 52 пациента с СД2 без переломов в анамнезе. Их возраст варьировал от 40 до 70 лет (средний возраст – 55,8±0,7 и 58,4±0,9 года соответственно). Контрольную группу составили 34 пациента (средний возраст – 55,9±0,9 года) без признаков СД в анамнезе. Пациенты с другими эндокринными нарушениями, с терминальной стадией осложнений и хроническими заболеваниями печени и почек были исключены из исследования. Определяли МПК методом рентгеновской абсорбциометрии (DXA), сывороточные маркеры костного ремоделирования (аминотерминальный пропептид проколлагена 1-го типа и С-терминальный телопептид), а также 25(ОН)D, паратирин, инсулин, гликированный гемоглобин (HbA1c), электролиты (Са2+, P+). Результаты и обсуждение. У пациентов с СД2 выявлена связь МПК с функцией почек, HbA1c и индексом массы тела. МПК в группе СД1 тесно связана с инсулиновой недостаточностью и была значимо ниже, чем в группе контроля. У пациентов с недостаточностью витамина D МПК была значительно ниже (p&lt;0,05), чем при нормальном его уровне. При СД1 выявлено как понижение МПК (p&lt;0,05), так и выраженное изменение уровней костных маркеров (p&lt;0,05). При СД2 нарушение процессов костного ремоделирования, которое определялось по уровню этих маркеров (p&lt;0,05), отмечалось на фоне нормальной МПК вследствие сложной патофизиологии основного заболевания. Заключение. Дефицит витамина D, недостаточность и снижение чувствительности к инсулину, гипергликемия, избыточная масса тела являются важными причинами остеопатии у пациентов с СД. Маркеры ремоделирования кости могут стать перспективными показателями для диагностики остеопатии, но требуются дополнительные исследования, направленные на разработку рекомендаций по их использованию в рутинной практике с целью прогнозирования и профилактики данного осложнения СД.</p></abstract><trans-abstract xml:lang="en"><p>Diabetic osteopathy is one of the little studied complications of diabetes mellitus (DM), which leads to common lowtrauma fractures and, as a consequence, disability and death. The level of insulin is connected with bone functional and morphological changes followed by decreased bone mineral density (BMD) in the early stages of diabetic osteopathy. Objective: to study bone morphofunctional properties in males with type 1 and 2 DM (T1DM and T2DM). Subjects and methods. Examinations were made in 41 male patients with T1DM and 52 male patients with T2DM without a history of fractures. Their age varied from 40 to 70 years (mean age, 55.8±0.7 years and 58.4±0.9 years, respectively). A control group consisted of 34 patients (mean age, 55.9±0.9 years) without a history of DM. Patients with other endocrine disorders, end-stage complications, or chronic liver and kidney diseases were excluded from the investigation. BMD was determined by dual-energy X-ray absorptiometry (DXA). Serum bone remodeling markers (procollagen type 1 amino-terminal propeptide and C-terminal telopeptide), as well as 25(OH)D, parathyrin, insulin, glycated hemoglobin (HbA1c), and electrolytes (Ca2+, P+) were evaluated. Results and discussion. An association of BMD with renal function, HbA1c, and body mass index was observed in patients with T2DM. In the T1MD group, BMD was closely related to insulin deficiency and was significantly lower than that in the control group. In patients with vitamin D deficiency, BMD was significantly lower than in those with normal vitamin D levels (p&lt;0.05). The patients with T1DM displayed both a decrease in BMD (p&lt;0.05) and a pronounced change in the levels of bone markers (p&lt;0.05). Those with T2DM had impaired bone remodeling processes, which was determined by the level of these markers (p&lt;0.05) and observed in the presence of normal BMD due to the complex pathophysiology of the underlying disease. Conclusion. Vitamin D deficiency, insufficient and decreased insulin sensitivity, hyperglycemia, and overweight are important causes of osteopathy in patients with DM. The markers of bone remodeling may become promising indicators for diagnosing osteopathy, but additional studies are needed to elaborate recommendations for their use in routine practice in order to predict and prevent this complication of DM.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>диабетическая остеопатия</kwd><kwd>маркеры костного ремоделирования</kwd><kwd>минеральная плотность кости</kwd></kwd-group><kwd-group xml:lang="en"><kwd>diabetic osteopathy</kwd><kwd>bone remodeling markers</kwd><kwd>bone mineral density</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">American Diabetes A. Standards of medical care in diabetes – 2018 Abridged for Primary Care Providers. Clin Diabet. 2018;36(1):14-37. doi: 10.2337/cd17-0119</mixed-citation><mixed-citation xml:lang="en">American Diabetes A. Standards of medical care in diabetes – 2018 Abridged for Primary Care Providers. Clin Diabet. 2018;36(1):14-37. doi: 10.2337/cd17-0119</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">International Diabetes Federation. Diabetes Atlas 2015: executive summary. 7th ed. Brussels: IDF; 2015.</mixed-citation><mixed-citation xml:lang="en">International Diabetes Federation. Diabetes Atlas 2015: executive summary. 7th ed. Brussels: IDF; 2015.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Carrillo-Lopez N, Roman-Garcia P, Rodriguez-Rebollar A, et al. Indirect regulation of PTH by estrogens may require FGF23. J Am Soc Nephrol. 2009;20(9):2009-17. doi: 10.1681/ASN.2008121258</mixed-citation><mixed-citation xml:lang="en">Carrillo-Lopez N, Roman-Garcia P, Rodriguez-Rebollar A, et al. Indirect regulation of PTH by estrogens may require FGF23. J Am Soc Nephrol. 2009;20(9):2009-17. doi: 10.1681/ASN.2008121258</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Farr JN, Drake MT, Amin S, et al. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res. 2014;29(4):787-95. doi: 10.1002/jbmr.2106</mixed-citation><mixed-citation xml:lang="en">Farr JN, Drake MT, Amin S, et al. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res. 2014;29(4):787-95. doi: 10.1002/jbmr.2106</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Farlay D, Armas LA, Gineyts E, et al. Nonenzymatic glycation and degree of mineralization are higher in bone from fractured patients with type 1 diabetes mellitus. J Bone Miner Res. 2016;31(1):190-5. doi: 10.1002/jbmr.2607</mixed-citation><mixed-citation xml:lang="en">Farlay D, Armas LA, Gineyts E, et al. Nonenzymatic glycation and degree of mineralization are higher in bone from fractured patients with type 1 diabetes mellitus. J Bone Miner Res. 2016;31(1):190-5. doi: 10.1002/jbmr.2607</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Farr JN, Khosla S. Determinants of bone strength and quality in diabetes mellitus in humans. Bone. 2016;82:28-34. doi: 10.1016/j.bone.2015.07.027</mixed-citation><mixed-citation xml:lang="en">Farr JN, Khosla S. Determinants of bone strength and quality in diabetes mellitus in humans. Bone. 2016;82:28-34. doi: 10.1016/j.bone.2015.07.027</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Sanches CP, Vianna AGD, Barreto FC. The impact of type 2 diabetes on bone metabolism. Diabetol Metab Syndr. 2017;9:85. doi:10.1186/s13098-017-0278-1</mixed-citation><mixed-citation xml:lang="en">Sanches CP, Vianna AGD, Barreto FC. The impact of type 2 diabetes on bone metabolism. Diabetol Metab Syndr. 2017;9:85. doi:10.1186/s13098-017-0278-1</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Diaz P, Barajas GS, Hernandez-Flores ZG, et al. The impact of vitamin D levels on glycemic control and bone mineral density in postmenopausal women with type 2 diabetes. J Endocrinol Invest. 2015;38(12):1365-72. doi: 10.1007/s40618-015-0394-4</mixed-citation><mixed-citation xml:lang="en">Diaz P, Barajas GS, Hernandez-Flores ZG, et al. The impact of vitamin D levels on glycemic control and bone mineral density in postmenopausal women with type 2 diabetes. J Endocrinol Invest. 2015;38(12):1365-72. doi: 10.1007/s40618-015-0394-4</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kanazawa I. Interaction between bone and glucose metabolism. Endocr J. 2017;64:1043-53. doi: 10.1507/endocrj.EJ17-0323</mixed-citation><mixed-citation xml:lang="en">Kanazawa I. Interaction between bone and glucose metabolism. Endocr J. 2017;64:1043-53. doi: 10.1507/endocrj.EJ17-0323</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Epstein S, Defeudis G, Manfrini S, et al. Diabetes and disordered bone metabolism (diabetic osteodystrophy): time for recognition. Osteoporos Int. 2016;27:1931-51. doi: 10.1007/s00198-015-3454-x</mixed-citation><mixed-citation xml:lang="en">Epstein S, Defeudis G, Manfrini S, et al. Diabetes and disordered bone metabolism (diabetic osteodystrophy): time for recognition. Osteoporos Int. 2016;27:1931-51. doi: 10.1007/s00198-015-3454-x</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ahmed N. Advanced glycation endproducts – role in pathology of diabetic complications. Diabetes Res Clin Pract. 2005;67(1):3- 21. doi: 10.1016/j.diabres.2004.09.004</mixed-citation><mixed-citation xml:lang="en">Ahmed N. Advanced glycation endproducts – role in pathology of diabetic complications. Diabetes Res Clin Pract. 2005;67(1):3- 21. doi: 10.1016/j.diabres.2004.09.004</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Chaiban JT, Nicolas KG. Diabetes and bone: still a lot to learn. Clin Rev Bone Miner Metab. 2015;13(1):20-35. doi: 10.1007/s12018-015-9178-9</mixed-citation><mixed-citation xml:lang="en">Chaiban JT, Nicolas KG. Diabetes and bone: still a lot to learn. Clin Rev Bone Miner Metab. 2015;13(1):20-35. doi: 10.1007/s12018-015-9178-9</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Chiu KC, Chu A, Go VLW, Saad MF. Hypovitaminosis D is associated with insulin resistance and β cell dysfunction. Am J Clin Nutr. 2004;79:820-5. doi: 10.1093/ajcn/79.5.820</mixed-citation><mixed-citation xml:lang="en">Chiu KC, Chu A, Go VLW, Saad MF. Hypovitaminosis D is associated with insulin resistance and β cell dysfunction. Am J Clin Nutr. 2004;79:820-5. doi: 10.1093/ajcn/79.5.820</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">De Liefde II, van der Klift M, De Laet CEDH, et al. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam study. Osteoporos Int. 2005;16:1713-20. doi: 10.1007/s00198-005-1909-1</mixed-citation><mixed-citation xml:lang="en">De Liefde II, van der Klift M, De Laet CEDH, et al. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam study. Osteoporos Int. 2005;16:1713-20. doi: 10.1007/s00198-005-1909-1</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Li Y, Liu H, Sato Y. The Association between the serum C-peptide level and bone mineral density. PLoS ONE. 2013;8(12):e83107. doi: 10.1371/journal.pone.0083107</mixed-citation><mixed-citation xml:lang="en">Li Y, Liu H, Sato Y. The Association between the serum C-peptide level and bone mineral density. PLoS ONE. 2013;8(12):e83107. doi: 10.1371/journal.pone.0083107</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Moreira CA, Barreto FC, Dempster DW. New insights on diabetes and bone metabolism. J Bras Nefrol. 2015;37(4):490-5. doi: 10.5935/0101-2800.20150077</mixed-citation><mixed-citation xml:lang="en">Moreira CA, Barreto FC, Dempster DW. New insights on diabetes and bone metabolism. J Bras Nefrol. 2015;37(4):490-5. doi: 10.5935/0101-2800.20150077</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Oei L, Rivadeneira F, Zillikens MC, Oei EHG. Diabetes, diabetic complications, and fracture risk. Curr Osteoporos Rep. 2015;13(2):106-15. doi: 10.1007/s11914-015-0260-5</mixed-citation><mixed-citation xml:lang="en">Oei L, Rivadeneira F, Zillikens MC, Oei EHG. Diabetes, diabetic complications, and fracture risk. Curr Osteoporos Rep. 2015;13(2):106-15. doi: 10.1007/s11914-015-0260-5</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Paschou SA, Dede AD, Anagnostis PG, et al. Type 2 diabetes and osteoporosis: a guide to optimal management. J Clin Endocrinol Metab. 2017;102(10):3621-34. doi: 10.1210/jc.2017-00042</mixed-citation><mixed-citation xml:lang="en">Paschou SA, Dede AD, Anagnostis PG, et al. Type 2 diabetes and osteoporosis: a guide to optimal management. J Clin Endocrinol Metab. 2017;102(10):3621-34. doi: 10.1210/jc.2017-00042</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Rubin MR. Bone cells and bone turnover in diabetes mellitus. Curr Osteoporos Rep. 2015;13(3):186-91. doi: 10.1007/s11914-015-0265-0</mixed-citation><mixed-citation xml:lang="en">Rubin MR. Bone cells and bone turnover in diabetes mellitus. Curr Osteoporos Rep. 2015;13(3):186-91. doi: 10.1007/s11914-015-0265-0</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Liao C-C, Lin C-S, Shih C-C, et al. Increased risk of fracture and postfracture adverse events in patients with diabetes: two nationwide population-based retrospective cohort studies. Diabetes Care. 2014;37:2246-52. doi: 10.2337/dc13-2957</mixed-citation><mixed-citation xml:lang="en">Liao C-C, Lin C-S, Shih C-C, et al. Increased risk of fracture and postfracture adverse events in patients with diabetes: two nationwide population-based retrospective cohort studies. Diabetes Care. 2014;37:2246-52. doi: 10.2337/dc13-2957</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Hernandez CJ, Tang SY, Baumbach BM, et al. Trabecular microfracture and the influence of pyridinium and non-enzymatic glycation-mediated collagen cross-links. Bone. 2005;37(6):825-32. doi: 10.1016/j.bone.2005.07.019</mixed-citation><mixed-citation xml:lang="en">Hernandez CJ, Tang SY, Baumbach BM, et al. Trabecular microfracture and the influence of pyridinium and non-enzymatic glycation-mediated collagen cross-links. Bone. 2005;37(6):825-32. doi: 10.1016/j.bone.2005.07.019</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
